Our Journey
➤ Journey starts as Seagull Laboratories. All founders quit comfortable jobs in MNC's and start gaining the trust of the medical fraternity.
➤ Inception of Seagull Pharmaceuticals, to manufacture our brands in-house.
➤ Launch of NVM tablet for managing neuropathy. Product is based on a unique concept and is an immediate success.
➤ Company breaks the price barrier for nimesulide tablets. Nimprex treats fever at just 40 paise/tablet.
➤ Launch of Superspas tablet/ injection for abdominal pain. Product is based on a unique concept and is an immediate success.
➤ Seagull enters the niche but rapidly growing derma cosmetics segment.
➤ Introduce Biomane for alopecia, a unique product which combines biotin with zinc.
➤ Introduce Noswet anti-perspirant, another novel concept.
➤ Company breaks the price barrier for levocetirizine tablets. Levotac treats allergies at just 50 paise/tablet.
➤ Revenue crosses 10 crores.
➤ Introduce Superspas antacid gel - a unique composition based on UKMHRA guidelines. Product gets immediate acceptance and helps grow the Superspas franchise.
➤ Price barrier broken for levocetirizine with montelukast tablets with the launch of Levotac-M tablets at only 5.90/ tablet.
➤ Revolutionise the migraine treatment market by introducing "Comig". Product gains immediate acceptance due to its unique composition.
➤ Revenue crosses 20 crores.
➤ Launch of CBcount tablet and syrup for patients with low platelets. Product is an immediate success because of its innovative composition which tackles all 5 challenges associated with dengue fever.
➤ Revenue crosses 40 crores
➤ Introduce the "fruit-laxative" concept. Launch Outlet drops, a unique and natural solution for paediatric constipation.
➤ Introduce Penova-IBS - The only enteric coated softgel capsules of peppermint oil for IBS patients
➤ Revenue crosses 50 crores
➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions" .
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific".
➤ Revenue crosses 60 crores despite Covid lockdowns.
➤ Seagull becomes the first Pharma company to bring Amber, an AI-enabled chatbot, on board as our Chief Listening Officer.
➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions"
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific".
➤ "Superspas" wins the "Perception that matters" Award from Pronto Consult.
➤ Launch of NVM-LC for patients of chronic fatigue. Product is an immediate success because of its innovative composition.
➤ Price barrier broken for bilastine with montelukast tablets with the launch of Alertac-M tablets at only 6.49/ tablet.
➤ Revenue crosses 80 crores
➤ Seagull ties up with micro learning platform byteEdge, to provide learning on the go to our sales team.
➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions" for the third successive year.
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific" for the third successive year.
➤ Further strengthen the Outlet franchise by introducing "Outlet" syrup for geriatric constipation
➤ Revenue crosses 90 crores